(Q37225766)

19 August 2017

0 references

Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations? (English)

1 reference

19 August 2017

1 reference

A Hauschild

1

1 reference

19 August 2017

1 May 2009

1 reference

19 August 2017

1 reference

19 August 2017

16

1 reference

19 August 2017

3

1 reference

19 August 2017

3-6

1 reference

Creative Commons Attribution 4.0 International

19 August 2017

start time

1 May 2009

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695706

Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695706

New promises in the adjuvant, and palliative treatment of melanoma.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695706

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695706

Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695706

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695706

Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695706

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695706

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695706

Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?

3 September 2018

1 reference

12 December 2020

Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma

1 reference

12 December 2020

Short German guidelines: malignant melanoma

1 reference

12 December 2020

Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?

1 reference

12 December 2020

Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up

1 reference

12 December 2020

Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha

1 reference

12 December 2020

Identifiers

DOI

10.3747/CO.V16I3.447

1 reference

19 August 2017

1 reference

PMC publication ID

2695706

19 August 2017

PubMed publication ID

19526078

1 reference

PMC publication ID

2695706